Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INFUSION TECHNOLOGY, INC.'S AMBULATORY IV PUMP

This article was originally published in The Gray Sheet

Executive Summary

INFUSION TECHNOLOGY, INC.'S AMBULATORY IV PUMP which "weighs less than one pound and is the size of a personal walkman stereo," according to the company, is scheduled for limited release to hospitals in November or December. Bolstered by a network of independent specialty distributors, ITI plans to move into the home health care market in early 1994. The pump has FDA 510(k) premarket clearance. Emphasizing the device's versatility in administering an assortment of medications under different conditions, ITI says the pump can be used "for multiple infusion therapies including pain management, chemotherapy, antibiotic therapy and TPN (total parenteral nutrition)." ITI acquired the pump, along with related patents and technologies, from Pfizer subsidiary Strato Medical. Pfizer acquired Strato in 1990. Known as "pumpman" at Strato (ITI has not yet unveiled its name for the device), the ambulatory intravenous infusion pump is the second product ITI has obtained from Strato. The first device, the Stratofuse PCA patient controlled analgesia pump and ambulatory infuser for programmable, multi-drug therapy, was acquired in 1992 and marked ITI's entry into the pain management arena. Stratoftise was launched by Strato in 1987, and marketed under an exclusive distribution agreement with Baxter between 1988 and 1992 when ITI assumed exclusive marketing rights. Citing Frost and Sullivan estimates, ITI says the ambulatory pump market is expected to exceed 20,000 units and $60 mil. in industry sales in 1993. The market has been growing 20% each year since 1988. Following completion of upgrades to the Stratofuse infuser, including increased programming capability and printer improvements, ITI is planning to market the Stratofuse PCA 11 "shortly," according to the company. Also slated for market introduction is an infusion device based on the principles of chronotherapy, "a treatment that schedules drug dosing according to the daily biological rhythms of the patient." According to ITI, "chronobiologic investigations have shown that the therapeutic effect and toxicity of drugs varies greatly with an individual's circadian cycle." Farther down the pike is a syringe infusion device geared for use by anesthesiologists in the operating room. ITI was founded in 1992 by two former Strato vice presidents and Robert Miller and Paul Fenton. Miller is president of ITI; Fenton oversees research and development. The company is located in Danvers, Massachusetts.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT001299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel